Palbociclib is an orally available, selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor, introduced as a targeted therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer. The gene discussed is NR4A1; the disease is breast cancer.